Metagenomi, Inc. (MGX)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Collaboration revenue | 8,513 | 4,127 | 11,514 | |
| Research and development | 22,507 | 25,142 | 26,256 | |
| General and administrative | 6,993 | 6,805 | 7,641 | |
| Total operating expenses | 29,500 | 31,947 | 33,897 | |
| Loss from operations | -20,987 | -27,820 | -22,383 | |
| Other expense, net | -70 | -8 | -57 | |
| Interest income | 2,485 | 2,887 | 3,616 | |
| Change in fair value of long-term investments | 1,292 | - | 2,055 | |
| Total other income, net | 1,123 | 2,879 | 1,504 | |
| Net loss before provision for income taxes | -19,864 | -24,941 | -20,879 | |
| Benefit (provision) for income taxes | 44 | 98 | -2,106 | |
| Net loss | -19,908 | -25,039 | -18,773 | |
| Unrealized loss on available-for-sale marketable securities | -249 | -88 | 1,904 | |
| Comprehensive loss | -20,157 | -25,127 | -16,869 | |
| Earnings per share, basic, total | -0.54 | -0.68 | -0.51 | |
| Earnings per share, diluted, total | -0.54 | -0.68 | -0.51 | |
| Weighted average number of shares outstanding, basic, total | 37,156,979 | 37,019,027 | 36,766,309 | |
| Weighted average number of shares outstanding, diluted, total | 37,156,979 | 37,019,027 | 36,766,309 | |